A citation-based method for searching scientific literature

Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S Multani, Alice T Shaw, Filippo G De Braud. Cancer Discov 2017
Times Cited: 448



Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K Lim, Shanna Stopatschinskaja, David M Hyman, Robert C Doebele, J Jean Cui, Alice T Shaw. Cancer Discov 2018
Times Cited: 190




List of shared articles



Times cited

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
0

The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Emily R Blauel, Theodore W Laetsch. Cancer Genet 2022
0

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi,[...]. Mol Cancer Res 2022
0

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal I Lindeman, Kathleen Moore, Shridar Ganesan, Christine M Lovly, Jane Perlmutter, Stacy W Gray, Jimmy Hwang,[...]. J Clin Oncol 2022
0

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
Guilherme Harada, Alexander Drilon. Cancer Genet 2022
0

Entrectinib, a new multi-target inhibitor for cancer therapy.
Qinghua Jiang, Mingxue Li, Hua Li, Lixia Chen. Biomed Pharmacother 2022
1

Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
0

Challenges and Opportunities in Cancer Drug Resistance.
Richard A Ward, Stephen Fawell, Nicolas Floc'h, Vikki Flemington, Darren McKerrecher, Paul D Smith. Chem Rev 2021
53

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
37

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena,[...]. Cancer Discov 2021
16


Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S Bowman, Marissa S Mattar, Inna Khodos, Elisa de Stanchina,[...]. Clin Cancer Res 2021
5

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
4


Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys.
Sijin Duan, Lin Dong, Bingsi Wang, Shujuan Wei, Xiaoyan Gong, Pengfei Yu, Chunmei Li, Yonglin Gao, Liang Ye, Hongbo Wang,[...]. Regul Toxicol Pharmacol 2021
2

Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka. Expert Opin Investig Drugs 2021
3

The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.
Paolo Tarantino, Luca Mazzarella, Antonio Marra, Dario Trapani, Giuseppe Curigliano. Cancer Treat Rev 2021
4

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Manali Tilak, Jennifer Holborn, Laura A New, Jasmin Lalonde, Nina Jones. Int J Mol Sci 2021
9

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Precision oncology in metastatic colorectal cancer - from biology to medicine.
Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni, Salvatore Siena, Josep Tabernero, Livio Trusolino, Rene Bernards, Alberto Bardelli. Nat Rev Clin Oncol 2021
24

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Theodore W Laetsch, David S Hong. Clin Cancer Res 2021
12